UroGen Pharma Ltd. (URGN)
URGN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$38.26
-0.05% on the day
Market cap
$1.9B
Small cap
Revenue · 2025
$109.8M
+21.4% on 2024
Net income · 2025
-$153.5M
-139.8% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | URGN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Israel |
| IPO year | 2017 |
| SEC CIK | 0001668243 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | L3 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $109.8M |
| Net income | -$153.5M |
| Operating income | -$124.9M |
| Net margin | -139.8% |
| Operating margin | -113.7% |
| Revenue growth | +21.4% |
| Cash | $110.7M |
| Total assets | $200.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 17.0× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2025-11-06 |
| Latest annual report FORM 10-K | 10-K | 2026-03-02 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-08-05 |
| Latest current report FORM 8-K | 8-K | 2026-08-20 |
| Latest proxy FORM DEF 14A | DEF 14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 579 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -9.2% |
| 1 month | -11.5% |
| 3 months | -7.6% |
| Year to date | +57.8% |
| 1 year | +120.5% |
| From 52-week high | -26.5% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| XERS | Xeris Biopharma Holdings Inc. | $10.20 | -2.49% | $1.9B |
| MLYS | Mineralys Therapeutics Inc. | $21.00 | -5.53% | $1.9B |
| PVLA | Palvella Therapeutics Inc. | $128.51 | -4.37% | $1.9B |
| ADRX | ADARx Pharmaceuticals Inc. | $17.70 | -1.50% | $1.9B |
| LKFT | Lakefront Biotherapeutics | $29.05 | -1.76% | $1.9B |
| VERA | Vera Therapeutics Inc. | $26.79 | -3.35% | $1.9B |
| SDGR | Schrodinger Inc. | $25.89 | -0.08% | $1.9B |
| AGIO | Agios Pharmaceuticals Inc. | $30.21 | -1.98% | $1.8B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier